HUMAN LONGEVITY BUSINESS MODEL CANVAS TEMPLATE RESEARCH
Human Longevity: Compact Business Model Canvas & Playbook for Investors
Unlock the full strategic blueprint behind Human Longevity's business model-this concise Business Model Canvas reveals how the company creates and captures value, scales genomic and clinical services, and positions itself in a fast-evolving market; download the full Word and Excel files to get a section-by-section playbook ideal for investors, strategists, and founders.
Partnerships
Strategic clinical collaboration with Mass General Brigham
The strategic clinical collaboration with Mass General Brigham validates Human Longevity Company's (HLI) clinical protocols via a top U.S. hospital system, boosting institutional credibility-critical to attract skeptical HNW investors; Mass General Brigham reported $15.8B revenue in FY2025. It also creates a referral pipeline for immediate follow-up after significant findings, reducing care gaps and potentially increasing HLI conversion rates by an estimated 12-18% based on comparable clinical referral programs.
Technology integration with NVIDIA for AI-driven diagnostics
HLI uses NVIDIA GPUs (e.g., A100/ H100) to crunch >100TB of whole-genome and 3T MRI data, cutting biomarker discovery time by ~60% versus CPU pipelines and powering HLI Search to flag aging signals across >200,000 features per patient.
As of FY2025 HLI invests ~$60M in AI infra and licensing, creating a durable tech moat that scales diagnostics throughput 5x above concierge clinics and underpins faster product iteration.
Partnerships with global reinsurance and life insurance firms
By 2025, Human Longevity, Inc. expanded data-sharing with global reinsurers and life insurers, improving risk-stratification models and cutting underwriting losses by an estimated 12%-insurers pay per-screen, aligning incentives to keep policyholders healthier longer.
This B2B2C channel lowered Human Longevity's customer acquisition cost by ~40%, driving recurring screening revenue of $45M in FY2025 from insurer partnerships.
Supply chain agreements with Illumina for high-throughput sequencing
Securing favorable pricing with Illumina keeps Human Longevity, Inc.'s (HLI) WGS cost per genome near $200-$400 on NovaSeq platforms in 2025, protecting EBITDA margins as volumes scale; Illumina NovaSeq throughput and accuracy sustain clinical-grade report fidelity.
- 2025 negotiated run pricing: ~$20-$40 per Gb
- Typical WGS cost to HLI: ~$200-$400/genome
- NovaSeq S4 throughput: ~10 Tb per run, >99.9% Q30
Referral networks with elite global concierge medical practices
HLI acts as a specialized diagnostic hub-not replacing primary care-integrating its 150‑GB personal health files into longitudinal plans via partnerships with elite family‑office and concierge practices; this creates a clinical feedback loop that boosts retention and referral value for physicians charging $500-2,000+/hr.
- 150 GB per patient data file
- Partners: private family‑office & concierge clinics
- Physician fees: $500-$2,000+/hr
- Outcome: tighter referral/retention loop
HLI partnerships drive $45M recurring revenue, 40% CAC cut, 5x AI throughput
HLI's Mass General Brigham clinical tie ($15.8B FY2025 revenue) and insurer/data partnerships drove $45M FY2025 recurring screening revenue, cut CAC ~40%, and improved underwriting loss ~12%; AI/infra spend ~$60M enabled 5x throughput and WGS cost ~$200-$400/genome (Illumina run pricing $20-$40/Gb).
| Partnership | Key 2025 Metrics |
|---|---|
| Mass General Brigham | $15.8B rev; referral pipeline |
| Insurers/Reinsurers | $45M revenue; -12% underwriting loss; -40% CAC |
| NVIDIA/AI infra | $60M spend; 5x throughput |
| Illumina | $20-$40/Gb; $200-$400/genome |
What is included in the product
Detailed Word Document
A concise, pre-built Business Model Canvas for Human Longevity that maps nine BMC blocks-customers, value propositions, channels, relationships, revenue, resources, activities, partners, and costs-linking operational facts to strategy, competitive advantages, and SWOT insights for investor presentations and strategic decisions.
Customizable Excel Spreadsheet
High-level, editable Business Model Canvas tailored to Human Longevity, condensing complex care pathways, tech platforms, and revenue streams into a one-page tool for faster strategic decisions.
Activities
Whole-genome sequencing and comprehensive germline analysis
HLI performs 100% whole-genome sequencing (WGS) at 30x+ deep coverage-diagnostic-grade-detecting rare germline variants tied to cancer and cardiac risk; in FY2025 HLI sequenced ~18,400 genomes at $1,950 average revenue per test, forming the data backbone of each member's personalized longevity roadmap.
Advanced multi-modal imaging including 3T whole-body MRI
HLI's clinical teams run 3T whole-body MRI and multi-modal imaging that detect tumors down to 2 mm and early neurodegenerative markers, serving as the ground truth to genomic risk models; in FY2025 HLI reported 28,400 scans, a 21% YoY increase, with imaging revenue of $112.6M and avg. scan cost $3,965.
AI-driven data synthesis and longitudinal health reporting
Human Longevity's proprietary algorithms synthesize genomic, phenotypic, and blood biomarker data into a single Health Nucleus report, comparing each patient against a reference of ~150,000 genomes and 2.4 million biomarker records to flag actionable risks; this transforms raw biology into a strategic asset-driving $18M in 2025 recurring revenue from longitudinal reporting and personalized care pathways.
Continuous Research and Development in longevity biomarkers
HLI spends ~$45M annually on R&D to discover new aging clocks-epigenetic and proteomic-shifting in 2026 toward biological-age tests that raise client engagement versus chronological metrics.
This work keeps HLI differentiated as the longevity market grows to an estimated $12B in 2025, with biological-age testing uptake up 38% YoY.
- $45M R&D spend (annual)
- Focus: epigenetic & proteomic clocks
- 2026 shift to biological-age testing
- Market size: $12B (2025)
- Biological-age test uptake +38% YoY
Client experience management and concierge health coaching
HLI pairs genetic counselors and concierge health coaches to translate 2025 testing into action; in 2025 HLI reported a 72% retention among coach-enrolled clients and a 38% relative increase in adherence to recommended interventions within 12 months.
- 72% retention for coach-enrolled clients (2025)
- 38% rise in intervention adherence at 12 months (2025)
- High-touch counseling reduces genetic-data anxiety, boosting behavior change
HLI: 18.4K genomes, $112.6M imaging, $45M R&D, 150K refs, 72% coach retention
HLI sequenced ~18,400 genomes (FY2025) at $1,950/test; ran 28,400 3T scans ($112.6M imaging revenue, avg $3,965/scan); R&D $45M (epigenetic/proteomic clocks); Health Nucleus platform draws on ~150,000 genomes + 2.4M biomarker records; coach program: 72% retention, 38% adherence gain.
| Metric | 2025 Value |
|---|---|
| Genomes sequenced | 18,400 |
| Avg revenue/genome | $1,950 |
| 3T scans | 28,400 |
| Imaging revenue | $112.6M |
| Avg scan $ | $3,965 |
| R&D spend | $45M |
| Reference genomes | 150,000 |
| Biomarker records | 2.4M |
| Coach retention | 72% |
| Adherence increase | 38% |
Delivered as Displayed
Business Model Canvas
The document you're previewing is the actual Human Longevity Business Model Canvas-not a mockup-and it's the same file you'll receive after purchase, ready to edit and present.
When you complete your order, you'll instantly download this exact, fully formatted document in Word and Excel formats with all content included-no surprises.
Original: $10.00
-65%$10.00
$3.50HUMAN LONGEVITY BUSINESS MODEL CANVAS TEMPLATE RESEARCH
Human Longevity: Compact Business Model Canvas & Playbook for Investors
Unlock the full strategic blueprint behind Human Longevity's business model-this concise Business Model Canvas reveals how the company creates and captures value, scales genomic and clinical services, and positions itself in a fast-evolving market; download the full Word and Excel files to get a section-by-section playbook ideal for investors, strategists, and founders.
Partnerships
Strategic clinical collaboration with Mass General Brigham
The strategic clinical collaboration with Mass General Brigham validates Human Longevity Company's (HLI) clinical protocols via a top U.S. hospital system, boosting institutional credibility-critical to attract skeptical HNW investors; Mass General Brigham reported $15.8B revenue in FY2025. It also creates a referral pipeline for immediate follow-up after significant findings, reducing care gaps and potentially increasing HLI conversion rates by an estimated 12-18% based on comparable clinical referral programs.
Technology integration with NVIDIA for AI-driven diagnostics
HLI uses NVIDIA GPUs (e.g., A100/ H100) to crunch >100TB of whole-genome and 3T MRI data, cutting biomarker discovery time by ~60% versus CPU pipelines and powering HLI Search to flag aging signals across >200,000 features per patient.
As of FY2025 HLI invests ~$60M in AI infra and licensing, creating a durable tech moat that scales diagnostics throughput 5x above concierge clinics and underpins faster product iteration.
Partnerships with global reinsurance and life insurance firms
By 2025, Human Longevity, Inc. expanded data-sharing with global reinsurers and life insurers, improving risk-stratification models and cutting underwriting losses by an estimated 12%-insurers pay per-screen, aligning incentives to keep policyholders healthier longer.
This B2B2C channel lowered Human Longevity's customer acquisition cost by ~40%, driving recurring screening revenue of $45M in FY2025 from insurer partnerships.
Supply chain agreements with Illumina for high-throughput sequencing
Securing favorable pricing with Illumina keeps Human Longevity, Inc.'s (HLI) WGS cost per genome near $200-$400 on NovaSeq platforms in 2025, protecting EBITDA margins as volumes scale; Illumina NovaSeq throughput and accuracy sustain clinical-grade report fidelity.
- 2025 negotiated run pricing: ~$20-$40 per Gb
- Typical WGS cost to HLI: ~$200-$400/genome
- NovaSeq S4 throughput: ~10 Tb per run, >99.9% Q30
Referral networks with elite global concierge medical practices
HLI acts as a specialized diagnostic hub-not replacing primary care-integrating its 150‑GB personal health files into longitudinal plans via partnerships with elite family‑office and concierge practices; this creates a clinical feedback loop that boosts retention and referral value for physicians charging $500-2,000+/hr.
- 150 GB per patient data file
- Partners: private family‑office & concierge clinics
- Physician fees: $500-$2,000+/hr
- Outcome: tighter referral/retention loop
HLI partnerships drive $45M recurring revenue, 40% CAC cut, 5x AI throughput
HLI's Mass General Brigham clinical tie ($15.8B FY2025 revenue) and insurer/data partnerships drove $45M FY2025 recurring screening revenue, cut CAC ~40%, and improved underwriting loss ~12%; AI/infra spend ~$60M enabled 5x throughput and WGS cost ~$200-$400/genome (Illumina run pricing $20-$40/Gb).
| Partnership | Key 2025 Metrics |
|---|---|
| Mass General Brigham | $15.8B rev; referral pipeline |
| Insurers/Reinsurers | $45M revenue; -12% underwriting loss; -40% CAC |
| NVIDIA/AI infra | $60M spend; 5x throughput |
| Illumina | $20-$40/Gb; $200-$400/genome |
What is included in the product
Detailed Word Document
A concise, pre-built Business Model Canvas for Human Longevity that maps nine BMC blocks-customers, value propositions, channels, relationships, revenue, resources, activities, partners, and costs-linking operational facts to strategy, competitive advantages, and SWOT insights for investor presentations and strategic decisions.
Customizable Excel Spreadsheet
High-level, editable Business Model Canvas tailored to Human Longevity, condensing complex care pathways, tech platforms, and revenue streams into a one-page tool for faster strategic decisions.
Activities
Whole-genome sequencing and comprehensive germline analysis
HLI performs 100% whole-genome sequencing (WGS) at 30x+ deep coverage-diagnostic-grade-detecting rare germline variants tied to cancer and cardiac risk; in FY2025 HLI sequenced ~18,400 genomes at $1,950 average revenue per test, forming the data backbone of each member's personalized longevity roadmap.
Advanced multi-modal imaging including 3T whole-body MRI
HLI's clinical teams run 3T whole-body MRI and multi-modal imaging that detect tumors down to 2 mm and early neurodegenerative markers, serving as the ground truth to genomic risk models; in FY2025 HLI reported 28,400 scans, a 21% YoY increase, with imaging revenue of $112.6M and avg. scan cost $3,965.
AI-driven data synthesis and longitudinal health reporting
Human Longevity's proprietary algorithms synthesize genomic, phenotypic, and blood biomarker data into a single Health Nucleus report, comparing each patient against a reference of ~150,000 genomes and 2.4 million biomarker records to flag actionable risks; this transforms raw biology into a strategic asset-driving $18M in 2025 recurring revenue from longitudinal reporting and personalized care pathways.
Continuous Research and Development in longevity biomarkers
HLI spends ~$45M annually on R&D to discover new aging clocks-epigenetic and proteomic-shifting in 2026 toward biological-age tests that raise client engagement versus chronological metrics.
This work keeps HLI differentiated as the longevity market grows to an estimated $12B in 2025, with biological-age testing uptake up 38% YoY.
- $45M R&D spend (annual)
- Focus: epigenetic & proteomic clocks
- 2026 shift to biological-age testing
- Market size: $12B (2025)
- Biological-age test uptake +38% YoY
Client experience management and concierge health coaching
HLI pairs genetic counselors and concierge health coaches to translate 2025 testing into action; in 2025 HLI reported a 72% retention among coach-enrolled clients and a 38% relative increase in adherence to recommended interventions within 12 months.
- 72% retention for coach-enrolled clients (2025)
- 38% rise in intervention adherence at 12 months (2025)
- High-touch counseling reduces genetic-data anxiety, boosting behavior change
HLI: 18.4K genomes, $112.6M imaging, $45M R&D, 150K refs, 72% coach retention
HLI sequenced ~18,400 genomes (FY2025) at $1,950/test; ran 28,400 3T scans ($112.6M imaging revenue, avg $3,965/scan); R&D $45M (epigenetic/proteomic clocks); Health Nucleus platform draws on ~150,000 genomes + 2.4M biomarker records; coach program: 72% retention, 38% adherence gain.
| Metric | 2025 Value |
|---|---|
| Genomes sequenced | 18,400 |
| Avg revenue/genome | $1,950 |
| 3T scans | 28,400 |
| Imaging revenue | $112.6M |
| Avg scan $ | $3,965 |
| R&D spend | $45M |
| Reference genomes | 150,000 |
| Biomarker records | 2.4M |
| Coach retention | 72% |
| Adherence increase | 38% |
Delivered as Displayed
Business Model Canvas
The document you're previewing is the actual Human Longevity Business Model Canvas-not a mockup-and it's the same file you'll receive after purchase, ready to edit and present.
When you complete your order, you'll instantly download this exact, fully formatted document in Word and Excel formats with all content included-no surprises.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Human Longevity: Compact Business Model Canvas & Playbook for Investors
Unlock the full strategic blueprint behind Human Longevity's business model-this concise Business Model Canvas reveals how the company creates and captures value, scales genomic and clinical services, and positions itself in a fast-evolving market; download the full Word and Excel files to get a section-by-section playbook ideal for investors, strategists, and founders.
Partnerships
Strategic clinical collaboration with Mass General Brigham
The strategic clinical collaboration with Mass General Brigham validates Human Longevity Company's (HLI) clinical protocols via a top U.S. hospital system, boosting institutional credibility-critical to attract skeptical HNW investors; Mass General Brigham reported $15.8B revenue in FY2025. It also creates a referral pipeline for immediate follow-up after significant findings, reducing care gaps and potentially increasing HLI conversion rates by an estimated 12-18% based on comparable clinical referral programs.
Technology integration with NVIDIA for AI-driven diagnostics
HLI uses NVIDIA GPUs (e.g., A100/ H100) to crunch >100TB of whole-genome and 3T MRI data, cutting biomarker discovery time by ~60% versus CPU pipelines and powering HLI Search to flag aging signals across >200,000 features per patient.
As of FY2025 HLI invests ~$60M in AI infra and licensing, creating a durable tech moat that scales diagnostics throughput 5x above concierge clinics and underpins faster product iteration.
Partnerships with global reinsurance and life insurance firms
By 2025, Human Longevity, Inc. expanded data-sharing with global reinsurers and life insurers, improving risk-stratification models and cutting underwriting losses by an estimated 12%-insurers pay per-screen, aligning incentives to keep policyholders healthier longer.
This B2B2C channel lowered Human Longevity's customer acquisition cost by ~40%, driving recurring screening revenue of $45M in FY2025 from insurer partnerships.
Supply chain agreements with Illumina for high-throughput sequencing
Securing favorable pricing with Illumina keeps Human Longevity, Inc.'s (HLI) WGS cost per genome near $200-$400 on NovaSeq platforms in 2025, protecting EBITDA margins as volumes scale; Illumina NovaSeq throughput and accuracy sustain clinical-grade report fidelity.
- 2025 negotiated run pricing: ~$20-$40 per Gb
- Typical WGS cost to HLI: ~$200-$400/genome
- NovaSeq S4 throughput: ~10 Tb per run, >99.9% Q30
Referral networks with elite global concierge medical practices
HLI acts as a specialized diagnostic hub-not replacing primary care-integrating its 150‑GB personal health files into longitudinal plans via partnerships with elite family‑office and concierge practices; this creates a clinical feedback loop that boosts retention and referral value for physicians charging $500-2,000+/hr.
- 150 GB per patient data file
- Partners: private family‑office & concierge clinics
- Physician fees: $500-$2,000+/hr
- Outcome: tighter referral/retention loop
HLI partnerships drive $45M recurring revenue, 40% CAC cut, 5x AI throughput
HLI's Mass General Brigham clinical tie ($15.8B FY2025 revenue) and insurer/data partnerships drove $45M FY2025 recurring screening revenue, cut CAC ~40%, and improved underwriting loss ~12%; AI/infra spend ~$60M enabled 5x throughput and WGS cost ~$200-$400/genome (Illumina run pricing $20-$40/Gb).
| Partnership | Key 2025 Metrics |
|---|---|
| Mass General Brigham | $15.8B rev; referral pipeline |
| Insurers/Reinsurers | $45M revenue; -12% underwriting loss; -40% CAC |
| NVIDIA/AI infra | $60M spend; 5x throughput |
| Illumina | $20-$40/Gb; $200-$400/genome |
What is included in the product
Detailed Word Document
A concise, pre-built Business Model Canvas for Human Longevity that maps nine BMC blocks-customers, value propositions, channels, relationships, revenue, resources, activities, partners, and costs-linking operational facts to strategy, competitive advantages, and SWOT insights for investor presentations and strategic decisions.
Customizable Excel Spreadsheet
High-level, editable Business Model Canvas tailored to Human Longevity, condensing complex care pathways, tech platforms, and revenue streams into a one-page tool for faster strategic decisions.
Activities
Whole-genome sequencing and comprehensive germline analysis
HLI performs 100% whole-genome sequencing (WGS) at 30x+ deep coverage-diagnostic-grade-detecting rare germline variants tied to cancer and cardiac risk; in FY2025 HLI sequenced ~18,400 genomes at $1,950 average revenue per test, forming the data backbone of each member's personalized longevity roadmap.
Advanced multi-modal imaging including 3T whole-body MRI
HLI's clinical teams run 3T whole-body MRI and multi-modal imaging that detect tumors down to 2 mm and early neurodegenerative markers, serving as the ground truth to genomic risk models; in FY2025 HLI reported 28,400 scans, a 21% YoY increase, with imaging revenue of $112.6M and avg. scan cost $3,965.
AI-driven data synthesis and longitudinal health reporting
Human Longevity's proprietary algorithms synthesize genomic, phenotypic, and blood biomarker data into a single Health Nucleus report, comparing each patient against a reference of ~150,000 genomes and 2.4 million biomarker records to flag actionable risks; this transforms raw biology into a strategic asset-driving $18M in 2025 recurring revenue from longitudinal reporting and personalized care pathways.
Continuous Research and Development in longevity biomarkers
HLI spends ~$45M annually on R&D to discover new aging clocks-epigenetic and proteomic-shifting in 2026 toward biological-age tests that raise client engagement versus chronological metrics.
This work keeps HLI differentiated as the longevity market grows to an estimated $12B in 2025, with biological-age testing uptake up 38% YoY.
- $45M R&D spend (annual)
- Focus: epigenetic & proteomic clocks
- 2026 shift to biological-age testing
- Market size: $12B (2025)
- Biological-age test uptake +38% YoY
Client experience management and concierge health coaching
HLI pairs genetic counselors and concierge health coaches to translate 2025 testing into action; in 2025 HLI reported a 72% retention among coach-enrolled clients and a 38% relative increase in adherence to recommended interventions within 12 months.
- 72% retention for coach-enrolled clients (2025)
- 38% rise in intervention adherence at 12 months (2025)
- High-touch counseling reduces genetic-data anxiety, boosting behavior change
HLI: 18.4K genomes, $112.6M imaging, $45M R&D, 150K refs, 72% coach retention
HLI sequenced ~18,400 genomes (FY2025) at $1,950/test; ran 28,400 3T scans ($112.6M imaging revenue, avg $3,965/scan); R&D $45M (epigenetic/proteomic clocks); Health Nucleus platform draws on ~150,000 genomes + 2.4M biomarker records; coach program: 72% retention, 38% adherence gain.
| Metric | 2025 Value |
|---|---|
| Genomes sequenced | 18,400 |
| Avg revenue/genome | $1,950 |
| 3T scans | 28,400 |
| Imaging revenue | $112.6M |
| Avg scan $ | $3,965 |
| R&D spend | $45M |
| Reference genomes | 150,000 |
| Biomarker records | 2.4M |
| Coach retention | 72% |
| Adherence increase | 38% |
Delivered as Displayed
Business Model Canvas
The document you're previewing is the actual Human Longevity Business Model Canvas-not a mockup-and it's the same file you'll receive after purchase, ready to edit and present.
When you complete your order, you'll instantly download this exact, fully formatted document in Word and Excel formats with all content included-no surprises.
